NEPHROS INC NEPH 深 滬
等待開盤 12-12 09:30:00 美东时间
4.97
-0.150
-2.93%
華盛通- 最 高5.15
- 今 開5.12
- 成交量 2.08万股
- 最 低 4.83
- 昨 收 5.12
- 總市值 5281.47万
- 52周最高 6.42
- 市盈率 靜 710.00
- 換手率 0.00%
- 52周最低 1.39
- 委 比 76.21%
- 總股本 1062.67万
- 歷史最高 11.666
- 量 比 0.22
- 振 幅 6.25%
- 歷史最低 0.905
- 每 手 1
- 風險率 1.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nephros and Medica Sign New Exclusive License And Supply Agreement; Company Has Agreed To Make Minimum Annual Aggregate Purchases From Medica Of €4,976,000, €5,349,000, €5,750,000, €6,000,000 And €6,300,000 For The Years 2026, 2027, 2028, 2029 And 2030, Respectively
On November 21, 2025, Nephros, Inc. (the "Company") entered into a license and supply agreement (the "License and Supply Agreement") with Medica S.p.A. ("Medica"), an Italy-based medical product manufacturing company,
11-27 05:20
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
¬Nephros Schedules Third Quarter 2025 Financial Results Conference Call
*Nephros, Inc. announces it will release third-quarter financial results on November 6, 2025, after market close and host a conference call at 4:30pm ET. Participants can join via domestic access: 1 (844) 808-7106 or international access: 1 (412) 317-5285, and ask to be connected to the Nephros conference. An audio archive will be available on the Nephros Investor Relations page shortly after the call and replay available until November 13, 2025,...
10-30 20:00
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
Neuphoria Therapeutics announced its Board has adopted a limited-duration stockholder rights plan to safeguard against rapid accumulation of its shares by investors. The plan aims to protect shareholder interests, ensure fair participation in strategic reviews, and prevent control without a premium. It does not hinder the Board from exploring strategic alternatives. The rights will trigger if any entity gains 15% ownership without Board approval,...
10-27 20:29
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
Neuphoria Therapeutics Inc. announced that its AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder (SAD) did not meet its primary or secondary endpoints. The company plans to discontinue further development of the SAD program and evaluate next steps for BNC210 in post-traumatic stress disorder (PTSD). Neuphoria will conduct a strategic review of its operations and portfolio. The company has $14.2 million in cash and expects to f...
10-20 20:15
Nephros Launches New PFAS Filter for Point-of-Use Protection of Potable Water
Nephros, Inc. has launched its new 19-Series PFAS Filter, designed to reduce Total PFAS in drinking water. Unlike most filters that target only PFOA and PFOS, this product addresses a broader range of PFAS contaminants, which are persistent and harmful to human health. The filter also removes other hazardous substances such as lead and asbestos, offering comprehensive protection. Key features include NSF certification, high capacity, and suitabil...
10-08 13:00
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Maxim Group Maintains Buy on Nephros, Raises Price Target to $6
Maxim Group analyst Anthony Vendetti maintains Nephros (NASDAQ:NEPH) with a Buy and raises the price target from $4.5 to $6.
08-09 06:58
Nephros shares are trading higher after the company reported better-than-expected Q2 financial results.
Nephros shares are trading higher after the company reported better-than-expect...
08-08 20:58
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
